Merck (NYSE: MRK) reported Q2 EPS of $1.01, $0.14 better than the analyst estimate of $0.87. Revenue for the quarter came in at $9.9 billion versus the consensus estimate of $9.75 billion.

• Second-Quarter 2017 Worldwide Sales Were $9.9 Billion, an Increase of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange
• Second-Quarter 2017 GAAP EPS Was $0.71; Second-Quarter Non-GAAP EPS Was $1.01
• Company Narrows and Raises 2017 Full-Year Revenue Range to be Between $39.4 Billion and $40.4 Billion, Including an Approximately 1 Percent Negative Impact from Foreign Exchange
• Company Reduces 2017 Full-Year GAAP EPS Range to be Between $1.60 and $1.72; Continues to Expect 2017 Full-Year Non-GAAP EPS Range to be Between $3.76 and $3.88, Including an Approximately 1 Percent Negative Impact from Foreign Exchange
• KEYTRUDA Development Program Significantly Advances with Several Key Regulatory Approvals
• Merck Enters Global Strategic Oncology Collaboration with AstraZeneca

GUIDANCE:

Merck sees FY2017 EPS of $3.76-$3.88, versus the consensus of $3.85. Merck sees FY2017 revenue of $39.4-40.4 billion, versus the consensus of $40.07 billion.

For earnings history and earnings-related data on Merck (MRK) click here.